Digital Library
Close Browse articles from a journal
     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             18 results found
no title author magazine year volume issue page(s) type
1 Bevacizumab for Brain Radiation Necrosis in Patients With Nonsquamous Nonsmall Cell Lung Cancer Shibahara, Daisuke

25 6 p. 581-586.e3
article
2 Clinicopathological Features and Survival Outcomes of Resected Lung Adenosquamous Carcinoma: Results From a Nationwide Japanese Registry Data Hishida, Tomoyuki

25 6 p. 519-528.e3
article
3 Editorial Board
25 6 p. A1
article
4 Factors Associated With Margin Positivity After Lung Resection Surgery Rshaidat, Hamza

25 6 p. 560-566
article
5 Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis? Muscolino, Paola

25 6 p. e262-e267
article
6 Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer Minne, Rachel L.

25 6 p. 567-576.e1
article
7 Impact of PROphet Test in Changing Physicians' Therapeutic Decision-Making for Checkpoint Immunotherapy in Non–Small-Cell Lung Cancer Gandara, David R.

25 6 p. e252-e261.e4
article
8 Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched‐Pair Cohort Study Using a Nationwide Inpatient Database Iwai, Chikako

25 6 p. e243-e251
article
9 MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC Reck, Martin

25 6 p. 587-593.e3
article
10 Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer Shah, Arpeet T.

25 6 p. 550-559
article
11 Patients' Preferences for Adjuvant Osimertinib in Non–Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients? Awidi, Muhammad

25 6 p. 509-518
article
12 Prediction of Pleural Lavage Cytology According to Thin-Section Computed Tomography in Non–Small-Cell Lung Cancer Nonaka, Yuto

25 6 p. 529-536
article
13 Refining Surveillance Guidelines after Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer Keltner, Samuel

25 6 p. e268-e276.e1
article
14 Surgery and Stereotactic Radiotherapy for Stage I Small-Cell Lung Carcinoma: A 25-Year Experience Robinson, Lary A.

25 6 p. 537-549.e2
article
15 Table of Contents
25 6 p. A3-A5
article
16 Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report Kleemiss, Moritz

25 6 p. 577-580
article
17 The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases Wu, Xiancheng

25 6 p. 483-501
article
18 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC Velcheti, Vamsidhar

25 6 p. 502-508.e3
article
                             18 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands